Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 6/20 | 0.80 |
| ▸ | AR | P10275 | 3/20 | 0.77 |
| ▸ | PGR | P06401 | 3/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.77 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.73 |
| ▸ | HRH1 | P35367 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | FNTA | P49354 | 1/20 | 0.66 |
| ▸ | FNTB | P49356 | 1/20 | 0.66 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.60 |
| ▸ | SHBG | P04278 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7616035 | 1.00 | NR3C1 (0.80) | NR3C1ARPGRHSD17B10HIF1A | |
| SCHEMBL11814068 | 0.92 | NR3C1 (0.77) | NR3C1ARPGRHSD17B10HIF1A | |
| SCHEMBL11814061 | 0.92 | NR3C1 (0.77) | NR3C1ARPGRHSD17B10HIF1A | |
| SCHEMBL3394719 | 0.92 | NR3C1 (0.80) | NR3C1ARPGRHSD17B10HIF1A | |
| SCHEMBL3394713 | 0.92 | NR3C1 (0.80) | NR3C1ARPGRHSD17B10HIF1A | |
| SCHEMBL13069232 | 0.92 | NR3C1 (0.80) | NR3C1ARPGRHSD17B10HIF1A | |
| SCHEMBL21231580 | 0.92 | NR3C1 (0.80) | NR3C1ARPGRHSD17B10HIF1A | |
| SCHEMBL8735123 | 0.90 | NR3C1 (0.87) | NR3C1ARPGRHSD17B10HIF1A | |
| SCHEMBL8735124 | 0.90 | NR3C1 (0.87) | NR3C1ARPGRHSD17B10HIF1A | |
| Fludrocortisone SCHEMBL23975175 | 0.89 | NR3C1 (1.00) | NR3C1ARPGRHSD17B10HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130237507-A1 | Novel Amide Compounds | ASTRAZENECA AB INTELLECTUAL PROPERTY (GB) | 2013-09-12 | — | — | US | disclosed |
| US-20130237507-A1 | Novel Amide Compounds | ASTRAZENECA AB INTELLECTUAL PROPERTY (GB) | 2013-09-12 | — | — | US | disclosed |
| US-20130237507-A1 | Novel Amide Compounds | ASTRAZENECA AB INTELLECTUAL PROPERTY (GB) | 2013-09-12 | — | — | US | disclosed |
| US-8338587-B2 | Compounds | ASTRAZENECA AB | 2012-12-25 | — | — | US | disclosed |
| US-8338587-B2 | Compounds | ASTRAZENECA AB | 2012-12-25 | — | — | US | disclosed |
| US-8338587-B2 | Compounds | ASTRAZENECA AB | 2012-12-25 | — | — | US | disclosed |
| US-20100256104-A1 | NOVEL AMIDE COMPOUNDS | ASTRAZENECA R&D (SE) | 2010-10-07 | — | — | US | disclosed |
| US-20100256103-A1 | NOVEL COMPOUNDS | ASTRAZENECA R&D (SE) | 2010-10-07 | — | — | US | disclosed |
| US-20100256103-A1 | NOVEL COMPOUNDS | ASTRAZENECA R&D (SE) | 2010-10-07 | — | — | US | disclosed |
| US-20100256103-A1 | NOVEL COMPOUNDS | ASTRAZENECA R&D (SE) | 2010-10-07 | — | — | US | disclosed |
| US-20100256104-A1 | NOVEL AMIDE COMPOUNDS | ASTRAZENECA R&D (SE) | 2010-10-07 | — | — | US | disclosed |
| US-20100256104-A1 | NOVEL AMIDE COMPOUNDS | ASTRAZENECA R&D (SE) | 2010-10-07 | — | — | US | disclosed |
| EP-0902789-B1 | ANDROSTENE DERIVATIVES | SOFT DRUGS INC (US) | 2002-01-23 | — | — | EP | disclosed |
| US-4996335-A | Soft steroids having anti-inflammatory activity | Bodor, Nicholas S. (US) | 1991-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256103-A1 | NOVEL COMPOUNDS | SLC10A1, ABCB1, UGT1A1 | NR3C1 858/4885AR 2439/4885PGR 681/4885 |
| US-20100256104-A1 | NOVEL AMIDE COMPOUNDS | H1-4, H1-3, H1-5 | NR3C1 2060/4885AR 835/4885PGR 454/4885 |
| US-20130237507-A1 | Novel Amide Compounds | H1-4, H1-3, H1-5 | NR3C1 1912/4885AR 802/4885PGR 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.